The efficacy of pregabalin was assessed in the first randomized, double-blind, placebo-controlled, multi-center clinical trial of patients with fibromyalgia (FM) in China (ClinicalTrials.gov.Identifier: NCT01387607). In total, 343 eligible patients were randomized (1:1) to receive 14 weeks of pregabalin (flexibly dosed 300–450 mg/day) or placebo. Pregabalin significantly improved the primary measure of pain reduction vs placebo at endpoint and every study week. The safety profile was consistent with the known profile of pregabalin. Post-hoc analyses summarized change from baseline to endpoint in mean pain scores (MPS) by age, gender, or dose (300/450 mg/day) subgroups using descriptive statistics. Patients with endpoint (Week 14) data were analyzed (pregabalin n = 128; placebo n = 124). Baseline MPS ranged from 5.8–6.6 across subgroups. Irrespective of subgroup, change from baseline in endpoint MPS was numerically greater for pregabalin vs placebo. Reduction (±standard deviation [SD]) in females (85%) was −2.14 ± 2.01 (pregabalin, n = 107) vs −1.41 ± 1.92 (placebo, n = 106) and −1.83 ± 2.23 (pregabalin, n = 21) vs −.70 ± 1.46 (placebo, n = 18) in males (15%). Reduction for ages 18–44 years (51%) was −1.81 ± 2.16 (pregabalin, n = 63) vs −1.39 ± 1.90 (placebo, n = 66) and −2.27 ± 1.88 (pregabalin, n = 62) vs −1.21 ± 1.88 (placebo, n = 56) for ages 45–64 years (47%). Patients aged >65 years were too few to assess (n = 5). The reduction in endpoint MPS by dose group in 300 mg/day dose group (17%) was −2.31 ± 1.92 (pregabalin, n = 27) vs −1.94 ± 1.61 (placebo equivalent, n = 16). Reduction for the 450 mg/day group (82.9%) was −2.03 ± 2.08 (pregabalin, n = 101) vs −1.21 ± 1.89 (placebo, n = 108). Overall, the numeric differences between pregabalin-treated subgroups by each stratum had overlapping values when considering SD, suggesting the differences between subgroups were not statistically meaningful. This finding also suggests flexible dose pregabalin (300–450 mg/day) may improve pain response across age, gender, or dose subgroups in terms of the mean change from baseline in the primary endpoint. This study was sponsored by Pfizer.